Europe presents a mature but steadily evolving market for ESKD treatment, supported by comprehensive healthcare systems, favorable reimbursement frameworks, and growing disease awareness. The region experiences a high burden of lifestyle-related diseases like diabetes and obesity, which contributes to a rising incidence of chronic kidney disease and progression to ESKD.
Drivers include increased government healthcare spending, technological advancements in dialysis devices, and the growing popularity of kidney transplant programs across EU countries. Germany, France, Italy, and the UK are the primary revenue contributors, with well-established nephrology infrastructures and clinical research capabilities.
A major restraint is the variability in healthcare access and quality across countries in Eastern and Southern Europe, which affects timely diagnosis and treatment outcomes. Additionally, the limited number of organ donors continues to restrict the growth of transplantation procedures.
Key trends shaping the European market include increased use of peritoneal dialysis, which offers more autonomy and lower infection risks, and the push toward greener dialysis technologies that reduce environmental impact. The region is also seeing rising investment in mobile health and remote patient management tools to support out-of-clinic care.
Opportunities are emerging through public-private partnerships aimed at improving patient education and early screening programs. Furthermore, the integration of electronic health records and AI is helping to optimize patient care pathways. As aging populations grow and lifestyle diseases persist, Europe is expected to experience steady demand for innovative and personalized ESKD treatment solutions.
TABLE - Europe Source: Company Publications, Primary Interviews, and SR Analysis
Europe 2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
CAGR (2024-2033)
U.K.
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Germany
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
France
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Total
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
TABLE - Europe End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Treatment Type 2021-2033
Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Hemodialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Peritoneal Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Kidney Transplantation | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Deceased Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Living Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Medications & Supportive Care | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Immunosuppressants | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Erythropoiesis-Stimulating Agents (ESA) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Phosphate Binders | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Europe End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Modality 2021-2033
Modality | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In-Center Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Home Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Europe End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By End-User 2021-2033
End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospitals & Clinics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Dialysis Centers | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Homecare Settings | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Research & Academic Institutes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Others | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis